1Ross JS, Symmans WF, Pusztai L,et al. Pharmacogenomics and clinical biomarkers in drug discovery and development [J]. Am J Clin Pathol. 2005,124 (Suppl) :29 -41.
2Lopez MF, Pluskal MG. Protein micro- and macroarrays: digitizing the proteome[ J ]. J Chromatogr B Analyt Technol Biomed Life Sci. 2003,787 ( 1 ) : 19 - 27.
3Verma M, Wright GL Jr, Hanash SM, et al. Proteomic approaches within the NCI early detection research network for the discovery and identification of cancer biomarkers [ J ]. Ann N Y Acad Sci ,2001,945( 1 ) :103 -115.
4Davidsson P, Puchades M, Blennow K. Identification of synaptic vesicle, pve-and postsynaptic proteins in human cerebrospinal fluid using liquid-phase isoelectric focusing[ J ]. Electrophoresis. 1999,20(3) : 431 -437.
5Hutter G,Sinha P. Proteomics for studying cancer cells and the development of chemoresistance [ J ]. Proteomics, 2001,1 (10) : 1233 - 1248.
6Jiang B,Bussey H,Roemer T. lead discovery[J]. Curr Opin -471Novel strategies in antifungalMicrobiol, 2002,5 ( 5 ) : 466-471.
7Ebrini I, Agnello D, Miller I, et al. Proteins of rat serum V : adjuvant arthritis and its modulation by nonsteroidal anti-inflammatory drugs [ J ]. Electrophoresis, 2000, 21 ( 11 ) :2170 - 2179.
8Gianazza E, Eberini 1, Villa P, et al. Monitoring the effects of drug treatment in rat models of disease by serum protein analysis [ J ]. J Chromatogr B Analyt Technol Biomed Life Sci,2002,771 ( 1 -2) :107 - 130.
9Roebuck BD, Curphey TJ, Li Y, et al. Evaluation of the cancer chemopreventive potency of dithiolethione analogs of oltipraz[ J]. Carcinogenesis ,2003,24(12) : 1919 - 1928.
10Wilkins MR. What do we want from proteomics in the detection and avoidance of adverse drug reactions [ J ]. Toxicology Letters,2002,127 ( 1 - 3 ) : 245 - 249.
8Mei Han,Jin-Kun Wen,Bin Zheng,et al.Acetylbritannilatone suppresses NO and PGE2 synthesis in RAW 264.7 macrophages through the inhibition of INOS and COX-2 gene expression.life Science.2004,(75):675-684.
